The effects of phenobarbital on serum high density lipoprotein subfractions and apolipoproteins.
Prospective studies report that a pharmacologic elevation of serum high density lipoprotein (HDL) concentration may be of value in the prevention of atherosclerosis. In this study phenobarbital, 50 mg at bedtime for ten days, increased serum HDL cholesterol, HDL2 cholesterol and HDL cholesterol/cholesterol and HDL cholesterol/apolipoprotein A-I ratios. Phenobarbital treated subjects had serum lipoprotein profile typical of low risk of ischemic heart disease.
Luoma
P V
PV
Department of Medicine, University of Oulu, Finland.
Marniemi
J
J
Sotaniemi
E A
EA
D000328:Adult; D016632:Apolipoprotein A-I; D001053:Apolipoproteins / Q000097:blood*; D001054:Apolipoproteins A / Q000097:blood; D001055:Apolipoproteins B / Q000097:blood; D002784:Cholesterol / Q000097:blood; D008076:Cholesterol, HDL / Q000097:blood*; D004338:Drug Combinations; D005260:Female; D006801:Humans; D008075:Lipoproteins, HDL / Q000097:blood*; D008297:Male; D010634:Phenobarbital / Q000097:blood / Q000494:pharmacology*; D013997:Time Factors
D016632:Apolipoprotein A-I; D001053:Apolipoproteins; D001054:Apolipoproteins A; D001055:Apolipoproteins B; D008076:Cholesterol, HDL; D004338:Drug Combinations; D008075:Lipoproteins, HDL; D002784:Cholesterol; D010634:Phenobarbital